Infection
Pre-septal peri-orbital cellulitis - outpatient treatment
Antibiotic Therapy (before prescribing, carefully read the Notes / Comments section below)

First line (if patient at low risk of C. difficile infection*):

Co-amoxiclav oral 625mg 8 hourly for 7 days


First line (if patient at high risk of C. difficile infection*):

Flucloxacillin oral 500mg 6 hourly for 7 days

and

Metronidazole oral 400mg 8 hourly for 7 days


First line (if penicillin / beta-lactam allergy):

Doxycycline oral 100mg 12 hourly for 7 days

N.B. In pregnant patients doxycycline is contraindicated.


Second line (if penicillin / beta-lactam allergy):

Levofloxacin oral 500mg 12 hourly for 7 days

and

Metronidazole oral 400mg 8 hourly for 7 days

In pregnant patients, levofloxacin is contraindicated - discuss appropriate empirical choices with an infection specialist.

Note that levofloxacin is an agent with a higher risk of causing C. difficile infection.*

Notes / Comments

Suspect orbital cellulitis if there is evidence of skin and soft tissue infection in the eye area with peri-orbital oedema, a displaced globe, double vision, ophthalmoplegia, or reduced visual acuity.

This is an emergency, as it is potentially sight-threatening, and any suspected case should be referred to secondary care for assessment and treatment.

In the ED: all cases of facial/peri-orbital cellulitis should be discussed with a senior member of ED medical staff and a maxillo-facial surgeon or ophthalmologist.

*Major risk factors for C. difficile infection (CDI):

Certain persons are at increased risk of acquiring CDI.

The possibility of CDI should be considered when persons with diarrhoea also have:

  • Current or recent (within the last three months) use of antimicrobial agents (especially those with a high risk for CDI, e.g. cephalosporins, broad spectrum penicillins, fluoroquinolones and clindamycin);
  • Increased age (>65 years old);
  • A previous diagnosis of CDI;
  • Prolonged hospital stay;
  • Serious underlying diseases;
  • Surgical procedures (in particular bowel procedures);
  • Immunosuppression (including HIV infection and transplant patients); and/or
  • Use of proton pump inhibitors (PPI)/H2 antagonists (drugs which reduce the production of stomach acid).

 

 

Guideline reviewed August 2023
Page updated March 2024



;